Skip to content
Back to search

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brimonidin (ausschl. DaFo Einzeldosen), ATC S01EA05 f. d. Z. 01.10.26 - 30.09.28 (zzgl. V.-Option 1x12 Mon)

DAK-GesundheitGermanyPublished on Aug 17, 2026
993 days left

Description

Section 130a, paragraph 8, of the German Social Code (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-specific, formal tendering procedures in accordance with the regulations of Part 4 of the German Competition Act (GWB). For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance Brimonidin (exclusively in the dosage form of single doses), ATC S01EA05, the DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract under the licensing model for the aforementioned substance will enter into force for the first time on 01.10.2026 and will end on 30.09.2028 (plus extension option 1x12 months). It will automatically end, regardless of this, with the entry into force of the exclusive contract.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders